UPB (Upstream Bio) Pre-Tax Income : $-37.23 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Upstream Bio's pretax income for the three months ended in Dec. 2024 was $-21.24 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-37.23 Mil. Upstream Bio's pretax margin was -3,465.25%.

During the past 3 years, Upstream Bio's highest Pretax Margin was -862.90%. The lowest was -3051.97%. And the median was -1969.31%.

Upstream Bio Pre-Tax Income Historical Data

The historical data trend for Upstream Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Pre-Tax Income Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-23.87

-20.54

-62.81

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial			-3.10	-11.83	-	-15.99	-21.24

Competitive Comparison of Upstream Bio's Pre-Tax Income

For the Biotechnology subindustry, Upstream Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Upstream Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Upstream Bio's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-77.764	+	2.835	+	0	+	12.123	+	7.105427357601E-15
	=	-62.81

Upstream Bio's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-26.318	+	0	+	0	+	5.076	+	0
	=	-21.24

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.23 Mil.

Upstream Bio (NAS:UPB) Pre-Tax Income Explanation

Upstream Bio's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-21.242	/	0.613
	=	-3,465.25%

During the past 3 years, Upstream Bio's highest Pretax Margin was -862.90%. The lowest was -3051.97%. And the median was -1969.31%.

Upstream Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.